Ultragenyx reports 96-week gene therapy data showing 61% lower cornstarch use
AI Summary- Ultragenyx announced publication of 96-week Phase 3 GENGLYCOS data for GSDIa patients.
- 61% mean cornstarch reduction was achieved by original and crossover participants at Week 96.
- DTX401 maintained a manageable two-year safety profile without reported class-related toxicity or malignancy.